Climb Bio, Inc. (fka Eliem Therapeutics) Files 8-K
Ticker: CLYM · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1768446
Sentiment: neutral
Topics: corporate-update, name-change
TL;DR
Climb Bio, Inc. (formerly Eliem Therapeutics) filed an 8-K on Oct 15, 2024, confirming its identity and address.
AI Summary
On October 15, 2024, Climb Bio, Inc. filed an 8-K report. The filing indicates that the company was formerly known as Eliem Therapeutics, Inc. and changed its name on February 19, 2019. Climb Bio, Inc. is incorporated in Delaware and its principal executive offices are located at 20 William Street, Suite 145, Wellesley Hills, Massachusetts.
Why It Matters
This filing confirms the corporate identity and history of Climb Bio, Inc., which is relevant for investors tracking the company's evolution and potential future activities.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain information that suggests immediate financial risk or opportunity.
Key Players & Entities
- Climb Bio, Inc. (company) — Registrant
- Eliem Therapeutics, Inc. (company) — Former company name
- February 19, 2019 (date) — Date of name change
- October 15, 2024 (date) — Date of report
- 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481 (address) — Principal Executive Offices
FAQ
What is the current name of the company filing this report?
The current name of the company is Climb Bio, Inc.
What was the company's former name?
The company was formerly known as Eliem Therapeutics, Inc.
When did the company change its name?
The company changed its name on February 19, 2019.
Where are Climb Bio, Inc.'s principal executive offices located?
Climb Bio, Inc.'s principal executive offices are located at 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481.
What is the date of this 8-K filing?
The date of this 8-K filing is October 15, 2024.
Filing Stats: 806 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-10-15 07:08:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CLYM The Nasdaq Stock Mar
- $218 million — eptember 30, 2024, it had approximately $218 million in cash, cash equivalents and marketabl
Filing Documents
- d889682d8k.htm (8-K) — 29KB
- d889682dex991.htm (EX-99.1) — 36KB
- g889682g1015040649737.jpg (GRAPHIC) — 4KB
- 0001193125-24-237196.txt ( ) — 234KB
- clym-20241015.xsd (EX-101.SCH) — 3KB
- clym-20241015_def.xml (EX-101.DEF) — 13KB
- clym-20241015_lab.xml (EX-101.LAB) — 22KB
- clym-20241015_pre.xml (EX-101.PRE) — 14KB
- d889682d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release dated October 15, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Climb Bio, Inc. Date: October 15, 2024 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer